An ansatz for the nonlinear Demkov-Kunike problem for cold molecule formation

We study nonlinear mean-field dynamics of ultracold molecule formation in the case when the external field configuration is defined by the level-crossing Demkov-Kunike model, characterized by a bell-shaped coupling and finite variation of the detuning. Analyzing the fast sweep rate regime of the strong interaction limit, which models a situation when the peak value of the coupling is large enough and the resonance crossing is sufficiently fast, we construct a highly accurate ansatz to describe the temporal dynamics of the molecule formation in the mentioned interaction regime. The absolute error of the constructed approximation is less than 3*10^-6 for the final transition probability while at certain time points it might increase up to 10^-3. Examining the role of the different terms in the constructed approximation, we prove that in the fast sweep rate regime of the strong interaction limit the temporal dynamics of the atom-molecule conversion effectively consists of the process of resonance crossing, which is governed by a nonlinear equation, followed by atom-molecular coherent oscillations which are basically described by a solution of the linear problem, associated with the considered nonlinear one.Comment: Accepted for publication in J. Contemp. Phys. (Armenian National Academy of Sciences) 8 pages, 4 figure

Theoretical model for ultracold molecule formation via adaptive feedback control

We investigate pump-dump photoassociation of ultracold molecules with amplitude- and phase-modulated femtosecond laser pulses. For this purpose a perturbative model for the light-matter interaction is developed and combined with a genetic algorithm for adaptive feedback control of the laser pulse shapes. The model is applied to the formation of 85Rb2 molecules in a magneto-optical trap. We find for optimized pulse shapes an improvement for the formation of ground state molecules by more than a factor of 10 compared to unshaped pulses at the same pump-dump delay time, and by 40% compared to unshaped pulses at the respective optimal pump-dump delay time. Since our model yields directly the spectral amplitudes and phases of the optimized pulses, the results are directly applicable in pulse shaping experiments

Demkov-Kunike model for cold atom association: weak interaction regime

We study the nonlinear mean-field dynamics of molecule formation at coherent photo- and magneto-association of an atomic Bose-Einstein condensate for the case when the external field configuration is defined by the quasi-linear level crossing Demkov-Kunike model, characterized by a bell-shaped pulse and finite variation of the detuning. We present a general approach to construct an approximation describing the temporal dynamics of the molecule formation in the weak interaction regime and apply the developed method to the nonlinear Demkov-Kunike problem. The presented approximation, written as a scaled solution to the linear problem associated to the nonlinear one we treat, contains fitting parameters which are determined through a variational procedure. Assuming that the parameters involved in the solution of the linear problem are not modified, we suggest an analytical expression for the scaling parameter.Comment: 6 pages, 4 figure

Formation of ultracold RbCs molecules by photoassociation

The formation of ultracold metastable RbCs molecules is observed in a double species magneto-optical trap through photoassociation below the ^85Rb(5S_1/2)+^133Cs(6P_3/2) dissociation limit followed by spontaneous emission. The molecules are detected by resonance enhanced two-photon ionization. Using accurate quantum chemistry calculations of the potential energy curves and transition dipole moment, we interpret the observed photoassociation process as occurring at short internuclear distance, in contrast with most previous cold atom photoassociation studies. The vibrational levels excited by photoassociation belong to the 5th 0^+ or the 4th 0^- electronic states correlated to the Rb(5P_1/2,3/2)+Cs(6S_1/2) dissociation limit. The computed vibrational distribution of the produced molecules shows that they are stabilized in deeply bound vibrational states of the lowest triplet state. We also predict that a noticeable fraction of molecules is produced in the lowest level of the electronic ground state

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study

Background. Breast cancer brain metastases (BCBM) are challenging complications that respond poorly to systemic therapy. The role of the blood–tumor barrier in limiting BCBM drug delivery and efficacy has been debated. Herein, we determined tissue and serum levels of capecitabine, its prodrug metabolites, and lapatinib in women with BCBM resected via medically indicated craniotomy. Methods. Study patients with BCBM requiring surgical resection received either single-dose capecitabine (1250 mg/m2 ) 2–3 h before surgery or 2–5 doses of lapatinib (1250 mg) daily, the last dose 2–3 h before surgery. Serum samples were collected serially on the day of surgery. Drug concentrations were determined in serum and BCBM using liquid chromatography tandem mass spectrometry. Results. Twelve patients were enrolled: 8 for capecitabine and 4 for lapatinib. Measurable drug levels of capecitabine and metabolites, 5′ -deoxy-5-fluorocytidine, 5′ -deoxy-5-fluorouridine, and 5-fluorouracil, were detected in all BCBM. The ratio of BCBM to serum was higher for 5-fluorouracil than for capecitabine. As for lapatinib, the median BCBM concentrations ranged from 1.0 to 6.5 mM. A high variability (0.19–9.8) was noted for lapatinib BCBM-to-serum ratio. Conclusions. This is the first study to demonstrate that capecitabine and lapatinib penetrate to a significant though variable degree in human BCBM. Drug delivery to BCBM is variable and in many cases appears partially limiting. Elucidating mechanisms that limit drug concentration and innovative approaches to overcome limited drug uptake will be important to improve clinical efficacy of these agents in the central nervous system.Trial registration ID: NCT00795678